Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

about

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice.

P2860

Q37160738-2E9195F4-2E2B-4BBC-BC43-A5DB9712705C

P2860

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

Item

http://www.wikidata.org/entity/Q35671461

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Integrated control of hyperten ...... and rationale for combination.

@ast

Integrated control of hyperten ...... and rationale for combination.

@en

type

Item

label

Integrated control of hyperten ...... and rationale for combination.

@ast

Integrated control of hyperten ...... and rationale for combination.

@en

prefLabel

Integrated control of hyperten ...... and rationale for combination.

@ast

Integrated control of hyperten ...... and rationale for combination.

@en

P1476

Integrated control of hyperten ...... and rationale for combination.

@en

P2093

Henry A Punzi

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Standards of medical care in diabetes--2011.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

P304

73-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IBPC.S12214

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22253546

http://www.w3.org/2001/XMLSchema#string

P932

3257873

http://www.w3.org/2001/XMLSchema#string

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

about

P2860

P2860

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932